|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Borley J, Wilhelm-Benartzi C, Brown R and
Ghaem-Maghami S: Does tumour biology determine surgical success in
the treatment of epithelial ovarian cancer? A systematic literature
review. Br J Cancer. 107:1069–1074. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
du Bois A, Quinn M, Thigpen T, Vermorken
J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A,
Cervantes A, et al: 2004 consensus statements on the management of
ovarian cancer: Final document of the 3rd international gynecologic
cancer intergroup ovarian cancer consensus conference (GCIG OCCC
2004). Ann Oncol. 16:VII7–VI12. 2005. View Article : Google Scholar
|
|
4
|
Japan society of gynecologic oncology:
Formulation committee of the treatment guidelines for ovarian.
https://jsgo.or.jp/guideline/ransou2015.htmlSeptember
1–2017
|
|
5
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R: Gynecologic Oncology Group: Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: A
gynecologic oncology group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Friedlander M, Trimble E, Tinker A,
Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S,
Pujade-Lauraine E, Sehouli J, et al: Int J Gynecol Cancer.
21:771–775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Markman M, Rothman R, Hakes T, Reichman B,
Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr: J Clin
Oncol. 9:389–393. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kyrgiou M, Salanti G, Pavlidis N,
Paraskevaidis E and Ioannidis JP: Survival benefits with diverse
chemotherapy regimens for ovarian cancer: Meta-analysis of multiple
treatments. J Natl Cancer Inst. 98:1655–1663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pelicano H, Carney D and Huang P: ROS
stress in cancer cells and therapeutic implications. Drug Resist
Updat. 7:97–110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alexandre J, Batteux F, Nicco C, Chéreau
C, Laurent A, Guillevin L, Weill B and Goldwasser F: Accumulation
of hydrogen peroxide is an early and crucial step for
paclitaxel-induced cancer cell death both in vitro and in vivo. Int
J Cancer. 119:41–48. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fruehauf J and Meyskens FL Jr: Reactive
oxygen species: A breath of life or death? Clin Cancer Res.
13:789–794. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boss O, Muzzin P and Giacobino JP: The
uncoupling proteins, a review. Eur J Endocrinol. 139:1–9. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fleury C and Sanchis D: The mitochondrial
uncoupling protein-2: Current status. Int J Biochem Cell Biol.
31:1261–1278. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baffy G: Uncoupling protein-2 and cancer.
Mitochondrion. 10:243–252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Echtay KS, Murphy MP, Smith RA, Talbot DA
and Brand MD: Superoxide activates mitochondrial uncoupling protein
2 from the matrix side. Studies using targeted antioxidants. J Biol
Chem. 277:47129–47135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Duval C, Nègre-Salvayre A, Dogilo A,
Salvayre R, Pénicaud L and Casteilla L: Increased reactive oxygen
species production with antisense oligonucleotides directed against
uncoupling protein 2 in murine endothelial cells. Biochem Cell
Biol. 80:757–764. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mattiasson G, Shamloo M, Gido G, Mathi K,
Tomasevic G, Yi S, Warden CH, Castilho RF, Melcher T,
Gonzalez-Zulueta M, et al: Uncoupling protein-2 prevents neuronal
death and diminishes brain dysfunction after stroke and brain
trauma. Nat Med. 9:1062–1068. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Teshima Y, Akao M, Jones SP and Marban E:
Uncoupling protein-2 overexpression inhibits mitochondrial death
pathway in cardiomyocytes. Circ Res. 93:192–200. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Horimoto M, Resnick MB, Konkin TA,
Routhier J, Wands JR and Baffy G: Expression of uncoupling
protein-2 in human colon cancer. Clin Cancer Res. 10:6203–6207.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carretero MV, Torres L, Latasa U,
Garcia-Trevijano ER, Prieto J, Mato JM and Avila MA: Transformed
but not normal hepatocytes express UCP2. FEBS Lett. 439:55–58.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Imai K, Fukuda T, Wada T, Kawanishi M,
Tasaka R, Yasui T and Sumi T: UCP2 expression may represent a
predictive marker of neoadjuvant chemotherapy effectiveness for
locally advanced uterine cervical cancer. Oncol Lett. 14:951–957.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Derdák Z, Fülöp P, Sabo E, Tavares R,
Berthiaume EP, Resnick MB, Paragh G, Wands JR and Baffy G: Enhanced
colon tumor induction in uncoupling protein-2 deficient mice is
associated with NF-kappaB activation and oxidative stress.
Carcinogenesis. 27:956–961. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Collins P, Jones C, Choudhury S, Damelin L
and Hodgson H: Increased expression of uncoupling protein 2 in
HepG2 cells attenuates oxidative damage and apoptosis. Liver Int.
25:880–887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
25
|
Pozza Dalla E, Fiorini C, Dando I,
Menegazzi M, Sgarbossa A, Costanzo C, Palmieri M and Donadelli M:
Role of mitochondrial uncoupling protein 2 in cancer cell
resistance to gemcitabine. Biochim Biophys Acta. 1823:1856–1863.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mailloux RJ, Adjeitey CN and Harper ME:
Genipin-induced inhibition of uncoupling protein-2 sensitizes
drug-resistant cancer cells to cytotoxic agents. PLoS One.
5:e132892010. View Article : Google Scholar : PubMed/NCBI
|
